News & Blog

NBTS Brain Tumor Clinical Trials Report: Q1 2021

It can be hard to keep track of new clinical trial opportunities opening across the United States, especially during the current public health crisis created by the coronavirus (COVID-19). However, there are many clinical trials still actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the party responsible for enrolling patients, just follow the hyperlink.**


  • Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma

    • Brief Description: This phase I clinical trial measures the amount and effect of lidocaine injected into patients with glioblastoma while they are undergoing surgical removal of their brain tumors. Lidocaine is a substance used to relieve pain by blocking signals at the nerve endings in skin. Information gained from this study may help researchers come up with new treatments to help patients with glioblastomas in the future.
  • Safety Study of Pritumumab in Brain Cancer
    • Brief Description: This is an open-label, phase II, outpatient, dose-escalation study of pritumumab in patients with brain cancer who have failed prior therapy and have no other available options. The trial will seek to determine the safety and/or tolerability and the recommended phase II dose of escalating, intravenously (IV) administered pritumumab.
  • A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
    • Brief Description:RSC-101 is a phase Ia/Ib clinical trial of RSC-1255 in adults studying participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have a disease that has progressed after standard therapy or have previously failed other therapies. Glioblastoma patients are eligible. The study has two phases. The purpose of phase Ia (Dose Escalation) is to confirm the appropriate treatment dose, and the purpose of phase Ib (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

*For a more comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder at trials.braintumor.org, where you can search potential opportunities for enrollment based on criteria important and specific to you.

**For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing patientnavigator@braintumor.org. Our patient navigator, Mary Lovely, PhD, RN, CNRN, has more than 30 years of experience working closely with brain tumor patients and families as a neurological nurse, clinical nurse specialist, and research nurse. Learn more here.

Post a Comment

Your email is kept private. Required fields are marked *

Share